Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapyVASSALOU, Helen; STATHOPOULOS, Efstathios; FIOLITAKI, Georgia et al.Lung cancer. 2013, Vol 82, Num 2, pp 324-329, issn 0169-5002, 6 p.Article

Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation statusKALIKAKI, Aristea; KOUTSOPOULOS, Anastasios; HATZIDAKI, Dora et al.Lung cancer. 2010, Vol 69, Num 1, pp 110-115, issn 0169-5002, 6 p.Article

Pemetrexed Versus Erlotinib in Pretreated Patients With Advanced Non-Small Cell Lung Cancer: A Hellenic Oncology Research Group (HORG) Randomized Phase 3 StudyKARAMPEAZIS, Athanasios; VOUTSINA, Alexandra; AGELAKI, Sofia et al.Cancer. 2013, Vol 119, Num 15, pp 2754-2764, issn 0008-543X, 11 p.Article

No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: A meta-analysisMING YIN; JINGRONG YAN; VOUTSINA, Alexandra et al.Lung cancer. 2011, Vol 72, Num 3, pp 370-377, issn 0169-5002, 8 p.Article